Literature DB >> 11118531

Desensitization, surface expression, and glycosylation of a functional, epitope-tagged type I PACAP (PAC(1)) receptor.

N Shintani1, H Hashimoto, A Kunugi, Y Koyama, K Yamamoto, S Tomimoto, W Mori, T Matsuda, A Baba.   

Abstract

To study desensitization and glycosylation of the type I pituitary adenylate cyclase-activating polypeptide (PACAP) receptor (PAC(1)R), a hemagglutinin (HA) epitope was inserted within the N-terminal extracellular domain, allowing immunological detection of PAC(1)R both in intact and permeabilized cells. PAC(1)R was tagged without loss of functions in ligand binding and ligand-stimulated cAMP production. In transiently transfected COS-7 cells, PAC(1)R was localized both in the plasma membrane and the cytoplasm around the nucleus. By immunoblot analysis, the immunoreactive bands with relative molecular masses ranging from 45 to 70 kDa were detected in the membrane fractions of PAC(1)R-expressing COS-7 cells. Digestion of the membranes with endoglycosidase F or treatment of the cells with tunicamycin decreased the size of the receptor to major bands of smaller size (approximately 45 and 48 kDa), suggesting that these two forms of PAC(1)R represent core proteins. Flow cytometric analysis indicated that the agonist promoted a disappearance of cell surface receptor. In accordance with this observation, preexposure of cells to PACAP38 induced a desensitization of PAC(1)R to the agonist response, although it did not cause a reduction in PAC(1)R mRNA or protein level and even slightly elevated them. These results suggest that agonist-induced desensitization of PAC(1)R involves the receptor sequestration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118531     DOI: 10.1016/s0005-2736(00)00295-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Lateralized hippocampal effects of vasoactive intestinal peptide on learning and memory in rats in a model of depression.

Authors:  Margarita Ivanova; Stiliana Belcheva; Iren Belcheva; Negrin Negrev; Roman Tashev
Journal:  Psychopharmacology (Berl)       Date:  2011-12-08       Impact factor: 4.530

2.  Cerebellar cortical-layer-specific control of neuronal migration by pituitary adenylate cyclase-activating polypeptide.

Authors:  D B Cameron; L Galas; Y Jiang; E Raoult; D Vaudry; H Komuro
Journal:  Neuroscience       Date:  2007-03-23       Impact factor: 3.590

3.  Stimulation of δ subunit-containing GABAA receptor by DS1 increases GnRH receptor expression but reduces GnRH mRNA expression in GnRH-producing GT1-7 cells.

Authors:  Unurjargal Sukhbaatar; Tselmeg Mijiddorj; Aki Oride; Haruhiko Kanasaki
Journal:  Endocrine       Date:  2014-10-30       Impact factor: 3.633

4.  The involvement of PACAP/VIP system in the synaptic transmission in the hippocampus.

Authors:  Kai Yang; Gang Lei; Michael F Jackson; John F Macdonald
Journal:  J Mol Neurosci       Date:  2010-04-23       Impact factor: 3.444

5.  Tachyphylaxis of the ECL-cell response to PACAP: receptor desensitization and/or depletion of secretory products.

Authors:  M Bernsand; R Håkanson; P Norlén
Journal:  Br J Pharmacol       Date:  2007-07-30       Impact factor: 8.739

6.  Role of kisspeptin and Kiss1R in the regulation of prolactin gene expression in rat somatolactotroph GH3 cells.

Authors:  Tomomi Hara; Haruhiko Kanasaki; Tuvshintugs Tumurbaatar; Aki Oride; Hiroe Okada; Satoru Kyo
Journal:  Endocrine       Date:  2018-09-25       Impact factor: 3.633

Review 7.  Role of PACAP in controlling granule cell migration.

Authors:  Donald Bryant Cameron; Emilie Raoult; Ludovic Galas; Yulan Jiang; Kimberly Lee; Taofang Hu; David Vaudry; Hitoshi Komuro
Journal:  Cerebellum       Date:  2009-06-23       Impact factor: 3.847

8.  Intranasal Administration of PACAP Is an Efficient Delivery Route to Reduce Infarct Volume and Promote Functional Recovery After Transient and Permanent Middle Cerebral Artery Occlusion.

Authors:  Asma Cherait; Julie Maucotel; Benjamin Lefranc; Jérôme Leprince; David Vaudry
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-20       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.